An open-label study to characterize the pharmacokinetic parameters of erlotinib (Tarceva, OSI 774) in cancer patients with advanced solid tumors, with adequate and moderately impaired hepatic function.
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Erlotinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 30 Jan 2011 Additional lead trial investigator (T R J Evans) identified as reported by United Kingdom Clinical Research Network.
- 30 Jan 2011 New source identified and integrated (United Kingdom Clinical Research Network; 9781).
- 15 Aug 2007 Status changed from recruiting to completed.